State Street Corp Acquires 1,895,529 Shares of Humacyte, Inc. (NASDAQ:HUMA)

State Street Corp grew its holdings in Humacyte, Inc. (NASDAQ:HUMA) by 66.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,764,155 shares of the company’s stock after acquiring an additional 1,895,529 shares during the quarter. State Street Corp’s holdings in Humacyte were worth $25,917,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of HUMA. nVerses Capital LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at approximately $28,000. Concurrent Investment Advisors LLC bought a new position in Humacyte in the third quarter valued at approximately $75,000. Principal Financial Group Inc. acquired a new position in shares of Humacyte in the second quarter valued at approximately $83,000. FORA Capital LLC bought a new stake in shares of Humacyte during the third quarter worth $96,000. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte during the second quarter worth $97,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Stock Up 34.1 %

HUMA stock opened at $4.64 on Monday. The company has a market cap of $583.99 million, a price-to-earnings ratio of -3.46 and a beta of 1.38. Humacyte, Inc. has a twelve month low of $2.48 and a twelve month high of $9.97. The business has a 50 day moving average price of $4.83 and a two-hundred day moving average price of $5.83. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HUMA. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Friday. TD Cowen restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $13.43.

Insider Activity

In other news, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is owned by insiders.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.